0001140361-17-002344.txt : 20170119
0001140361-17-002344.hdr.sgml : 20170119
20170119213344
ACCESSION NUMBER: 0001140361-17-002344
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170117
FILED AS OF DATE: 20170119
DATE AS OF CHANGE: 20170119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bailey Sue
CENTRAL INDEX KEY: 0001403769
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 17537422
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DRIVE
STREET 2: SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20850
4
1
doc1.xml
FORM 4
X0306
4
2017-01-17
0
0001367644
Emergent BioSolutions Inc.
EBS
0001403769
Bailey Sue
400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG
MD
20879
1
0
0
0
Common Stock
2016-08-01
4
J
0
152
0.0
A
34637
D
Common Stock
2016-08-01
4
J
0
604
0.00
A
35241
D
Common Stock
2016-08-01
4
J
0
577
0.00
A
35818
D
Common Stock
2017-01-17
4
M
0
3157
10.64
A
38975
D
Common Stock
2017-01-17
4
S
0
3157
29.7789
D
35818
D
Common Stock
2017-01-17
4
M
0
3157
14.71
A
38975
D
Common Stock
2017-01-17
4
S
0
3157
29.7789
D
35818
D
Common Stock
2017-01-17
4
M
0
3157
20.08
A
38975
D
Common Stock
2017-01-17
4
S
0
3157
29.7789
D
35818
D
Common Stock
2017-01-17
4
M
0
4735
13.37
A
40553
D
Common Stock
2017-01-17
4
S
0
4735
29.7789
D
35818
D
Common Stock
2017-01-17
4
M
0
3157
13.00
A
38975
D
Common Stock
2017-01-17
4
S
0
3157
29.7789
D
35818
D
Common Stock
2017-01-17
4
M
0
2061
18.64
A
37879
D
Common Stock
2017-01-17
4
S
0
2061
29.7789
D
35818
D
Stock Option (Right to buy)
10.64
2016-08-01
4
J
0
277
0
A
2019-05-20
Common Stock
277
3157
D
Stock Option (Right to buy)
10.64
2017-01-17
4
M
0
3157
0
D
2019-05-20
Common Stock
3157
0
D
Stock Option (Right to buy)
14.71
2016-08-01
4
J
0
277
0
A
2020-05-19
Common Stock
277
3157
D
Stock Option (Right to buy)
14.71
2017-01-17
4
M
0
3157
0
D
2020-05-19
Common Stock
3157
0
D
Stock Option (Right to buy)
20.08
2016-08-01
4
J
0
416
0
A
2021-05-18
Common Stock
416
4736
D
Stock Option (Right to buy)
20.08
2017-01-17
4
M
0
3157
0
D
2021-05-18
Common Stock
3157
1579
D
Stock Option (Right to buy)
13.37
2016-08-01
4
J
0
693
0
A
2019-05-16
Common Stock
693
7893
D
Stock Option (Right to buy)
13.37
2017-01-17
4
M
0
4735
0
D
2019-05-16
Common Stock
4735
3158
D
Stock Option (Right to buy)
13.00
2016-08-01
4
J
0
693
0
A
2020-05-22
Common Stock
693
7893
D
Stock Option (Right to buy)
13.00
2017-01-17
4
M
0
3157
0
D
2020-05-22
Common Stock
3157
4736
D
Stock Option (Right to buy)
18.64
2016-08-01
4
J
0
905
0
A
2021-05-21
Common Stock
905
10305
D
Stock Option (Right to buy)
18.64
2017-01-17
4
M
0
2061
0
D
2021-05-21
Common Stock
2061
8244
D
In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017.
In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.
In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive.
In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off.
The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.
/s/ Eric Burt, Attorney-in-fact
2017-01-19